Boehringer Ingelheim Report Results of BI 695501 in P-III Trial for Patients with Crohn’s Disease

 Boehringer Ingelheim Report Results of BI 695501 in P-III Trial for Patients with Crohn’s Disease

Boehringer Ingelheim and Zealand Pharma to Initiate P-II Study of BI 456906 for Obesity and Diabetes

Shots:

  • The P-III study involves assessing BI 695501 vs Abbvie’s Humira in 147 patients with mod. to sev. CD that were either TNF naïve or prior treated with infliximab
  • The P-III study results demonstrated non-inferior efficacy and similar safety profile to the reference product, met its 1Eps i.e, CDAI response @4wks. (89.7% vs 94.4%); infection rates (23.6% vs 22.7%); safety was similar b/w the group with no new safety signals
  • BI 695501 is biosimilar referencing AbbVie’s Humira, approved by the US FDA and EMA in 2017 as Cyltezo for multiple chronic inflammatory diseases

Click here Click here to read full press release/ article | Ref: empr, clinical trials | Image: Signbox

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post